CD52-Negative NK cells are abundant in the liver and less susceptible to alemtuzumab treatment

CD52-Negative NK cells are abundant in the liver and less susceptible to alemtuzumab treatment

<strong>Background</strong> T-cell depleting strategies have become an integral part of immunosuppressive regimens in organ transplantation. Alemtuzumab is a humanized monoclonal antibody against CD52, a cell-surface antigen on several immune cells. It has been suggested that lymphocyte...

書誌詳細
主要な著者:	Hotta, R, Ohira, M, Matsuura, T, Muraoka, I, Tryphonopoulos, P, Fan, J, Tekin, A, Selvaggi, G, Levi, D, Ruiz, P, Ricordi, C, Vianna, R, Ohdan, H, Waldmann, H, Tzakis, A, Nishida, S
フォーマット:	Journal article
言語:	English
出版事項:	Public Library of Science 2016

類似資料

CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
著者:: Ryuichi Hotta, 等
出版事項: (2016-01-01)

Clinical-Scale Isolation of Interleukin-2-Stimulated Liver Natural Killer Cells for Treatment of Liver Transplantation with Hepatocellular Carcinoma
著者:: Masahiro Ohira, 等
出版事項: (2012-07-01)

Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis
著者:: Wendy Gilmore, 等
出版事項: (2020-06-01)

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
著者:: Lundin, J, 等
出版事項: (2002)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
著者:: Hale, G, 等
出版事項: (2002)

Hepatic irradiation persistently eliminates liver resident NK cells.
著者:: Ryosuke Nakano, 等
出版事項: (2018-01-01)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
著者:: Chakrabarti, S, 等
出版事項: (2004)

ALEMTUZUMAB INDUCTION IN PANCREAS TRANSPLANTATION
著者:: Muthusamy, A, 等
出版事項: (2011)

Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.
著者:: Sambasiva P Rao, 等
出版事項: (2012-01-01)

Alemtuzumab: right drug, right dose?
著者:: Haynes, R, 等
出版事項: (2011)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
著者:: Clatworthy, MR, 等
出版事項: (2009)

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
著者:: Watson, C, 等
出版事項: (2004)

Typhlitis as a complication of alemtuzumab therapy
著者:: I. Marie, 等
出版事項: (2007-05-01)

Systematic reviews of alemtuzumab in renal transplantation.
著者:: O'Callaghan, J, 等
出版事項: (2013)

Systematic reviews of alemtuzumab in renal transplantation
著者:: O'Callaghan, J, 等
出版事項: (2013)

Hepatectomy leads to loss of TRAIL-expressing liver NK cells via downregulation of the CXCL9-CXCR3 axis in mice.
著者:: Takuya Yano, 等
出版事項: (2017-01-01)

Alemtuzumab in the up-front setting
著者:: Matthew Kaufman, 等
出版事項: (2008-04-01)

Alemtuzumab in the treatment of multiple sclerosis
著者:: Fernandez Ó
出版事項: (2014-02-01)

Identification of alemtuzumab-suitable multiple sclerosis patients in Slovakia and sequencing of post-alemtuzumab immunomodulatory treatment
著者:: Ema Kantorová, 等
出版事項: (2024-10-01)

Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab.
著者:: Avivi, I, 等
出版事項: (2004)

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
著者:: Hale, G, 等
出版事項: (2004)

The CAMPATH-1 antigen (CDw52).
著者:: Hale, G, 等
出版事項: (1990)

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
著者:: Watson, C, 等
出版事項: (2005)

Alemtuzumab in treatment of chronic lymphocytic leukemia
著者:: S. S. Bessmeltsev, 等
出版事項: (2022-11-01)

Inclusion Body Myositis Treated with Alemtuzumab
著者:: Juliana Sá, 等
出版事項: (2019-12-01)

Alemtuzumab induction and steroid free immunosupprssion in pancreas transplantation.
著者:: Muthusamy, A, 等
出版事項: (2007)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
著者:: Havrdova E, 等
出版事項: (2017-10-01)

Acute portal hypertension using portal vein ligation abrogates TRAIL expression of liver‐resident NK cells
著者:: Yuki Imaoka, 等
出版事項: (2022-09-01)

Alemtuzumab and Natalizumab: The Monoclonal Antibody Story Continues
著者:: BL Johnston, 等
出版事項: (2006-01-01)

Listeria Meningitis with Aspergillosis After Alemtuzumab Treatment
著者:: Ahmet Kasım Kılıç, 等
出版事項: (2022-03-01)

Clinical efficacy and safety of alemtuzumab in postmarketing practice
著者:: N. V. Khachanova
出版事項: (2019-06-01)

Mycobacterium haemophilum Infection after Alemtuzumab Treatment
著者:: Mini Kamboj, 等
出版事項: (2008-11-01)

Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation.
著者:: Muthusamy, A, 等
出版事項: (2008)

Steroid-free immunosuppression in pancreas transplantation using Alemtuzumab induction
著者:: Muthusamy, A, 等
出版事項: (2007)

Evaluating Predictors of Quality in Liver NK Cells Among Deceased Donors
著者:: Yuki Imaoka, 等
出版事項: (2024-10-01)

The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer’s perspective
著者:: Luis J. Pastor-Quirós, 等
出版事項: (2021-10-01)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
著者:: Katja Akgün, 等
出版事項: (2018-03-01)

Anti-glomerular basement membrane disease after alemtuzumab.
著者:: Clatworthy, MR, 等
出版事項: (2008)

Effects of Alemtuzumab on (Auto)antigen-Specific Immune Responses
著者:: Clara Hilger, 等
出版事項: (2020-10-01)

OP 2.5 – 00048 Targeting the SIV reservoir with Alemtuzumab
著者:: B. Varco-Merth, 等
出版事項: (2022-12-01)